IS2681B - Efnablöndur með tafða losun sem fela í sér lamótrígín - Google Patents

Efnablöndur með tafða losun sem fela í sér lamótrígín

Info

Publication number: IS2681B
Authority: IS; Iceland
Prior art keywords: delayed release; preparations containing; release preparations; containing lamotrigine; lamotrigine
Prior art date: 2002-07-29

Application number

IS7707A

Other languages

English (en)

Other versions

IS7707A (is

Inventor

Ian Richard Buxton

Robin Currie

Myrna A Dela-Cruz

Gary Wayne Goodson

Wlodzimierz Karolak

Mehran Maleki

Vijay Mohan Iyer

Gopal Muppirala

Alan Frank Parr

Singh Jagdev Sidhu

Robert Allen Stagner

Akunuri Venkata Vijay-Kumar

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-29

Filing date

2005-02-23

Publication date

2010-09-15

2002-07-29 Priority claimed from GB0217492A external-priority patent/GB0217492D0/en

2002-07-29 Priority claimed from GB0217493A external-priority patent/GB0217493D0/en

2003-06-13 Priority claimed from GB0313801A external-priority patent/GB0313801D0/en

2005-02-23 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2005-02-23 Publication of IS7707A publication Critical patent/IS7707A/is

2010-09-15 Publication of IS2681B publication Critical patent/IS2681B/is

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hematology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS7707A 2002-07-29 2005-02-23 Efnablöndur með tafða losun sem fela í sér lamótrígín IS2681B (is)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0217492A GB0217492D0 (en)	2002-07-29	2002-07-29	Novel method of treatment
GB0217493A GB0217493D0 (en)	2002-07-29	2002-07-29	Novel methods of treatment
GB0313801A GB0313801D0 (en)	2003-06-13	2003-06-13	Novel methods of treatment
PCT/EP2003/008368 WO2004012741A1 (en)	2002-07-29	2003-07-28	Sustained release formulations comprising lamotrigine

Publications (2)

Publication Number	Publication Date
IS7707A IS7707A (is)	2005-02-23
IS2681B true IS2681B (is)	2010-09-15

Family

ID=31499035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7707A IS2681B (is)	2002-07-29	2005-02-23	Efnablöndur með tafða losun sem fela í sér lamótrígín

Country Status (28)

Country	Link
US (1)	US20050032799A1 (is)
EP (1)	EP1524981B1 (is)
JP (2)	JP4744142B2 (is)
KR (1)	KR100882707B1 (is)
CN (1)	CN100363007C (is)
AR (1)	AR040709A1 (is)
AT (1)	ATE424827T1 (is)
AU (1)	AU2003260336C1 (is)
BR (1)	BRPI0313148B8 (is)
CA (1)	CA2493301A1 (is)
CO (1)	CO5680405A2 (is)
CY (1)	CY1109119T1 (is)
DE (1)	DE60326590D1 (is)
DK (1)	DK1524981T3 (is)
ES (1)	ES2323268T3 (is)
IL (1)	IL166424A (is)
IS (1)	IS2681B (is)
MA (1)	MA27509A1 (is)
MX (1)	MXPA05001243A (is)
MY (1)	MY141049A (is)
NO (1)	NO334221B1 (is)
NZ (1)	NZ537885A (is)
PL (1)	PL213565B1 (is)
PT (1)	PT1524981E (is)
RU (1)	RU2325163C2 (is)
SI (1)	SI1524981T1 (is)
TW (1)	TWI342213B (is)
WO (1)	WO2004012741A1 (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7939102B2 (en) *	2002-06-07	2011-05-10	Torrent Pharmaceuticals Ltd.	Controlled release formulation of lamotrigine
EP1524981B1 (en) *	2002-07-29	2009-03-11	Glaxo Group Limited	Sustained release formulations comprising lamotrigine
JP2007512350A (ja) *	2003-11-25	2007-05-17	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	カルベジロール組成物の治療および送達方法
US20060039975A1 (en) *	2004-08-20	2006-02-23	Zalman Vilkov	Paroxetine formulations
US8058291B2 (en) *	2005-04-06	2011-11-15	Adamas Pharmaceuticals, Inc.	Methods and compositions for the treatment of CNS-related conditions
WO2008109343A1 (en) *	2007-03-01	2008-09-12	Memory Pharmaceuticals Corporation	Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
US20090022789A1 (en) *	2007-07-18	2009-01-22	Supernus Pharmaceuticals, Inc.	Enhanced formulations of lamotrigine
US8486927B2 (en) *	2007-11-09	2013-07-16	Thar Pharmaceuticals	Crystalline forms of lamotrigine
US20090196924A1 (en) *	2008-02-04	2009-08-06	Pramod Kharwade	Controlled-release lamotrigine formulations
MX2011000636A (es) *	2008-07-18	2011-08-03	Valeant Pharmaceuticals Int	Formulacion de liberacion modificada y metodos de uso.
US20100323015A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
US20100323016A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
BR112012013487A2 (pt)	2009-12-02	2017-10-03	Adamas Pharmaceuticals Inc	Composições de amantadina e métodos de uso
WO2011086568A1 (en) *	2010-01-13	2011-07-21	Accutest Research Laboratories (I) Pvt. Ltd	Controlled release composition for lamotrigine
BR112013019791A2 (pt) *	2011-02-03	2016-10-25	Lupin Ltd	composições farmacêuticas de bepotastina de liberação oral controlada
WO2014159275A1 (en) *	2013-03-14	2014-10-02	PharmTak, Inc.	Controlled-release pharmaceutical compositions comprising lamotrigine and methods of producing same
CN103920134A (zh) *	2014-05-08	2014-07-16	崔韡	一种治疗儿童眩晕的缓释片及其制备方法
RU2624229C2 (ru) *	2015-12-21	2017-07-03	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Таблетки клозапина с замедленным высвобождением и способ их получения
RU2613192C1 (ru) *	2016-02-18	2017-03-15	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Таблетки клозапина с пролонгированным высвобождением
CN110545818A (zh) *	2017-02-03	2019-12-06	朱比兰特医药有限公司	拉莫三嗪悬浮剂剂型
IL272834B2 (en)	2017-08-24	2024-08-01	Adamas Pharma Llc	Amantadine compositions, preparations thereof, and methods of use
US20200318189A1 (en) *	2017-10-27	2020-10-08	Chang Gung Memorial Hospital, Linkou	Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
US10213393B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság	Composition and method for treating neurological disease
US10213394B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
US20190247331A1 (en)	2018-02-15	2019-08-15	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
AU2019261406A1 (en) *	2018-04-25	2020-12-17	Neurocentria, Inc.	Magnesium threonate compositions and uses thereof
CN114948868B (zh) *	2021-04-16	2023-04-14	上海奥科达医药科技股份有限公司	一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物
CN116942606A (zh) *	2022-04-18	2023-10-27	上海奥科达医药科技股份有限公司	拉莫三嗪悬浮液和干混悬剂的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704295A (en) *	1983-09-19	1987-11-03	Colorcon, Inc.	Enteric film-coating compositions
US4556552A (en) *	1983-09-19	1985-12-03	Colorcon, Inc.	Enteric film-coating compositions
JPH0667828B2 (ja) *	1985-10-09	1994-08-31	日研化学株式会社	バルプロ酸ナトリウムの持続性顆粒製剤
US4775536A (en) *	1986-02-24	1988-10-04	Bristol-Myers Company	Enteric coated tablet and process for making
US4816262A (en) *	1986-08-28	1989-03-28	Universite De Montreal	Controlled release tablet
GB8820353D0 (en) *	1988-08-26	1988-09-28	Staniforth J N	Controlled release tablet
IL91398A (en) *	1988-08-30	1994-05-30	Pfizer	Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US5827819A (en) *	1990-11-01	1998-10-27	Oregon Health Sciences University	Covalent polar lipid conjugates with neurologically active compounds for targeting
ES2083074T3 (es) *	1991-11-13	1996-04-01	Glaxo Canada	Dispositivo de liberacion controlada.
IT1266565B1 (it) *	1993-07-22	1997-01-09	Ct Lab Farm Srl	Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5733575A (en) *	1994-10-07	1998-03-31	Bpsi Holdings, Inc.	Enteric film coating compositions, method of coating therewith, and coated forms
AUPN605795A0 (en) *	1995-10-19	1995-11-09	F.H. Faulding & Co. Limited	Analgesic pharmaceutical composition
AU4078897A (en) *	1996-08-23	1998-03-06	Algos Pharmaceutical Corporation	Anticonvulsant containing composition for treating neuropathic pain
GB9625795D0 (en) *	1996-12-12	1997-01-29	Smithkline Beecham Plc	Novel treatment
US6046716A (en) *	1996-12-19	2000-04-04	Colorado Microdisplay, Inc.	Display system having electrode modulation to alter a state of an electro-optic layer
CA2216215A1 (en) *	1997-04-05	1998-10-05	Isa Odidi	Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
GB9726987D0 (en) *	1997-12-22	1998-02-18	Glaxo Group Ltd	Compounds
RU2246295C2 (ru) *	1998-11-02	2005-02-20	Элзэ Копэрейшн	Лекарственная форма c постоянной скоростью высвобождения лекарственного вещества, ядро лекарственной формы и способ обеспечения облегченного высвобождения лекарственного вещества из лекарственной формы
GB9930079D0 (en) *	1999-12-20	2000-02-09	Glaxo Group Ltd	Medicaments
GB0024517D0 (en) *	2000-10-06	2000-11-22	Glaxo Group Ltd	Use of medicaments
DE10224170A1 (de) *	2002-05-31	2003-12-11	Desitin Arzneimittel Gmbh	Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
EP1524981B1 (en) *	2002-07-29	2009-03-11	Glaxo Group Limited	Sustained release formulations comprising lamotrigine

2003
- 2003-07-28 EP EP03766343A patent/EP1524981B1/en not_active Expired - Lifetime
- 2003-07-28 PT PT03766343T patent/PT1524981E/pt unknown
- 2003-07-28 AR AR20030102702A patent/AR040709A1/es not_active Application Discontinuation
- 2003-07-28 AT AT03766343T patent/ATE424827T1/de active
- 2003-07-28 PL PL374982A patent/PL213565B1/pl unknown
- 2003-07-28 JP JP2004525362A patent/JP4744142B2/ja not_active Expired - Lifetime
- 2003-07-28 WO PCT/EP2003/008368 patent/WO2004012741A1/en not_active Ceased
- 2003-07-28 NZ NZ537885A patent/NZ537885A/en not_active IP Right Cessation
- 2003-07-28 DE DE60326590T patent/DE60326590D1/de not_active Expired - Lifetime
- 2003-07-28 AU AU2003260336A patent/AU2003260336C1/en not_active Expired
- 2003-07-28 ES ES03766343T patent/ES2323268T3/es not_active Expired - Lifetime
- 2003-07-28 MX MXPA05001243A patent/MXPA05001243A/es active IP Right Grant
- 2003-07-28 CN CNB038223716A patent/CN100363007C/zh not_active Expired - Lifetime
- 2003-07-28 TW TW092120477A patent/TWI342213B/zh not_active IP Right Cessation
- 2003-07-28 RU RU2005105353/14A patent/RU2325163C2/ru active
- 2003-07-28 MY MYPI20032831A patent/MY141049A/en unknown
- 2003-07-28 BR BRPI0313148A patent/BRPI0313148B8/pt not_active IP Right Cessation
- 2003-07-28 SI SI200331585T patent/SI1524981T1/sl unknown
- 2003-07-28 DK DK03766343T patent/DK1524981T3/da active
- 2003-07-28 CA CA002493301A patent/CA2493301A1/en not_active Withdrawn
- 2003-07-28 KR KR1020057001633A patent/KR100882707B1/ko not_active Expired - Lifetime
- 2003-07-29 US US10/629,177 patent/US20050032799A1/en not_active Abandoned
2005
- 2005-01-20 IL IL166424A patent/IL166424A/en unknown
- 2005-01-28 MA MA28074A patent/MA27509A1/fr unknown
- 2005-01-28 CO CO05007005A patent/CO5680405A2/es not_active Application Discontinuation
- 2005-02-22 NO NO20050948A patent/NO334221B1/no not_active IP Right Cessation
- 2005-02-23 IS IS7707A patent/IS2681B/is unknown
2009
- 2009-05-29 CY CY20091100580T patent/CY1109119T1/el unknown
2010
- 2010-10-15 JP JP2010232745A patent/JP2011057683A/ja active Pending

Also Published As

Publication number	Publication date
CY1109119T1 (el)	2014-07-02
TW200418484A (en)	2004-10-01
NO334221B1 (no)	2014-01-13
ES2323268T3 (es)	2009-07-10
JP2005538113A (ja)	2005-12-15
WO2004012741A1 (en)	2004-02-12
BRPI0313148B1 (pt)	2019-08-20
MA27509A1 (fr)	2005-09-01
AU2003260336A1 (en)	2004-02-23
CO5680405A2 (es)	2006-09-29
DE60326590D1 (de)	2009-04-23
RU2005105353A (ru)	2005-10-27
IS7707A (is)	2005-02-23
MY141049A (en)	2010-02-25
CN100363007C (zh)	2008-01-23
KR100882707B1 (ko)	2009-02-06
PL213565B1 (pl)	2013-03-29
AU2003260336C1 (en)	2008-05-29
BR0313148A (pt)	2005-07-12
ATE424827T1 (de)	2009-03-15
BRPI0313148B8 (pt)	2021-05-25
CN1681509A (zh)	2005-10-12
JP2011057683A (ja)	2011-03-24
PT1524981E (pt)	2009-06-17
IL166424A (en)	2010-12-30
JP4744142B2 (ja)	2011-08-10
MXPA05001243A (es)	2005-06-08
HK1077003A1 (en)	2006-02-03
TWI342213B (en)	2011-05-21
AR040709A1 (es)	2005-04-13
EP1524981A1 (en)	2005-04-27
PL374982A1 (en)	2005-11-14
KR20050026054A (ko)	2005-03-14
CA2493301A1 (en)	2004-02-12
RU2325163C2 (ru)	2008-05-27
DK1524981T3 (da)	2009-06-22
NO20050948L (no)	2005-02-22
IL166424A0 (en)	2006-01-15
EP1524981B1 (en)	2009-03-11
NZ537885A (en)	2007-11-30
US20050032799A1 (en)	2005-02-10
SI1524981T1 (sl)	2009-08-31

Publication	Publication Date	Title
IS2681B (is)	2010-09-15	Efnablöndur með tafða losun sem fela í sér lamótrígín
IS2946B (is)	2016-05-15	Lyfjablanda sem felur í sér andrógen
DE60235896D1 (de)	2010-05-20	Verzögerte freigabe von mikrokristallin peptidsuspensionen
GB0229015D0 (en)	2003-01-15	New Compound
EP1542699A4 (en)	2009-03-25	COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
DE60308880D1 (en)	2006-11-16	Embolisation
IS7177A (is)	2004-03-11	Valdekoxíb samsetningar sem leysast upp í munni
AU2003212776A1 (en)	2003-10-08	Microparticles
IL165572A0 (en)	2006-01-15	1-Ä(indoÜ-3-yl)carbonylÜpiperazine derivatives
IS7190A (is)	2004-03-19	Aðferðir og blöndur sem fela í sér ný tríasínefnasambönd
AU2003220466A1 (en)	2004-04-19	Delayed release dosage forms
PL397821A1 (pl)	2012-03-12	Związek1-acetylo-6-fluoro-2-indolinon
GB0204241D0 (en)	2002-04-10	Compound
DE60320722D1 (de)	2008-06-19	Teilchenoptische Systeme
DE03791054T1 (de)	2005-10-20	Partikel-Trennvorrichtung
GB0224830D0 (en)	2002-12-04	Compound
DE50307407D1 (de)	2007-07-19	Strömungsbremse
DE60302376D1 (de)	2005-12-29	Schutzschalter
DE60329987D1 (en)	2009-12-24	Embolisation
GB0213027D0 (en)	2002-07-17	Compound
AT500592B1 (de)	2006-08-15	Entstörgerät
GB2376164B (en)	2003-07-09	Trap
GB0220046D0 (en)	2002-10-09	Starfish trap
CA94671S (en)	2002-02-15	Sink
CA94675S (en)	2002-02-15	Sink